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The objective ofthis study was to develop arapid in vitro method for predicting the response
of human tumors to anticancer drugs. In this study an attempt was made to correlate the drug
effects on the relative incorporation of(3H) thymidine (ThdR) into DNA with thesensitivity of
tumor cells to that drug. The results ofthe study indicate that following treatment of the cells
with adriamycin (ADR) or 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1 nitrosourea (MeCCNU),
there was a significant inhibition ofDNA synthesis in the drug-sensitive cells. However, the in-
hibition was relatively small in the drug-resistant cells. Following cytosine arabinoside (Ara-C)
treatment, a dramatic recovery in the rate of DNA synthesis was seen in Ara-C-resistant cells
but not in cells sensitive to Ara-C. Thus, the method described in this study appears to be
capable of distinguishing whether a tumor cell line is sensitive or resistant to a given drug.
INTRODUCTION
Although there is no panacea for all neoplastic diseases, a variety of agents that
possess antineoplastic activity have been discovered. Unfortunately, patients' re-
sponses to a given drug vary over a wide range [1]. Thus, a patient may or may not
respond well to a particular treatment or may require several trial therapies before
an effective treatment is found.
A solution for avoiding ineffective and unnecessary chemotherapeutic regimens
would be to develop a rapid in vitro method that would predict the best drugs to use
for agiven patient based on the drug sensitivity ofthatpatient's tumor cells. Most of
the anticancer agents in use today not only inhibit cell division but also cause dam-
age to DNA, evidenced as chromosome lesions. A method that was developed to
screen for mutagenic agents on the basis oftheir ability to inhibit DNA synthesis in
HeLa cells [2-4] may also be useful to predict the response ofhuman tumors to anti-
cancer drugs. The object of this study was to ascertain whether or not this method
can indeed distinguish tumor cell lines of known sensitivity to a specific drug from
those that are resistant to the drug.
MATERIALS AND METHODS
Cells
Mouse leukemia cell lines, P-388/0 (P-388 mouse leukemia cells sensitive to all
drugs listed in this study), P-388/ADR(adriamycin-resistant mouse leukemiacells),
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All rights of reproduction in any form reserved.and P-388/Ara-C (cytosine arabinoside-resistant mouse leukemia cells) were kindly
supplied by Dr. Lee Wilkoff of Southern Research Institute, Birmingham, Ala-
bama. The P-388/ADR resistant cell line is actually a vincristine-resistant cell line
found to be cross-resistant to 0.02-2.0 Ag/ml concentrations of adriamycin as deter-
mined using a semisolid medium plating assay. p values of <0.0001 were obtained
for all drug concentrations within the 0.02-2.0 Ag/ml range when comparing P-388/
ADR and P-388/O cell survival following drug treatment [5]. Both P-388/ADR and
P-388/Ara-C drug-resistant cell lines were established by treatment of (C57BL 6 x
DBA/2 6 (BDFJ) mice bearing ascites tumor with vincristine or Ara-C, respectively,
over a number of transplant generations [5]. The cell lines were maintained in cul-
ture as was previously described [5]. The three cell lines were routinely grown in
Falcon 75 cm2 tissue culture flasks (Falcon Plastics, Oxnard, CA) at 37°C in a hu-
midified CO2 incubator in RPMI-1640 medium with L-glutamine (Grand Island
Biological Co., Santa Clara, CA) supplemented with 16 percent heat-inactivated
fetal calf serum and a 1 percent antibiotic mixture (10,000 U penicillin/ml and
10,000 Ag streptomycin/ml).
Two human colon cancer cell lines, HT-29 (MeCCNU-resistant), originally iso-
lated by Fogh and Trempe [6], and the cell line BE (MeCCNU-sensitive) were kindly
supplied by Dr. Kurt Kohn of the National Institutes of Health, Bethesda, Mary-
land. The BE and HT-29 cell lines were determined to be sensitive and resistant,
respectively, using both in vivo and in vitro tests [13]. We also performed an in vitro
study on the sensitivity and resistance of the two cell lines. Following a one-hour ex-
posure to 2.5, 5, and 10Ag/ml concentrations of MeCCNU, the HT-29 drug-treated
cells, when compared to untreated cells, had a 100 percent relative plating efficiency
at all concentrations tested, whereas drug-treated BE cells had a 11.3 percent, 2.25
percent, and 0 percent relative plating efficiency, respectively, when compared to
untreated cells. These two cell lines were routinely grown as monolayer cultures in
Falcon plastic dishes at 37°C in a humidified CO2 incubator in McCoy's modified
medium 5-A (Grand Island Biological Co., Santa Clara, CA), supplemented with
the amounts of fetal calf serum and antibiotics used in the RPMI-1640 medium.
Drugs
Ara-C (Upjohn) was dissolved in specially provided bacteriostatic water for injec-
tion with benzyl alcohol 0.9 percent weight per volume to give a stock solution of
20 mg/ml. ADR (Adria Laboratories, Inc., Columbus, OH) was dissolved in 0.9
percent NaCl to give a stock solution of 2 mg/ml. MeCCNU (NSC-95441) was dis-
solved in specially provided diluent to give a stock solution of 25 mg/ml. Stock solu-
tions of all the drugs were prepared just before use, and the desired concentrations
were obtained by serial dilution with complete culture medium.
Measurement ofDrug Effects on DNA Synthesis in Tumor Cells
Human colon cancer cell lines, i.e., BE and HT-29, were plated in a number of
35 mm plastic dishes (Lux, Newbury Park, CA) one or two days before the experi-
ment. The experiment was begun by adding ( 14C) ThdR (0.01 ,^Ci/ml; specific activ-
ity 30 Ci/mM) to all the dishes and incubating them for 24 hours. At the end of this
incubation (14C) ThdR was removed; the cells were washed with fresh medium and
then exposed to different drug concentrations for 30 minutes. Cells incubated in
medium containing no drug served as a control. The cells were washed free of drug
and reincubated in regular medium. At 0, 0.5, and 1.5 hours after the removal of the
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drug, the cells were pulsed with(3H) ThdR (3 ACi/ml) for ten minutes and then
washed three times with ice-cold SSC (0.15 M sodium chloride-0.015 M sodium
citrate). The cells were then scraped with a rubber policeman into cold 4 percent
perchloric acid (PCA), transferred to a filter paper, washed three times with cold
PCA, and dehydrated by washing serially with 70 percent, 95 percent, and 100 per-
cent ethanol. The filter paper with cells was dried under a heat lamp and then trans-
ferred to a scintillation vial containing 10 ml Scinti Verse (Fisher Scientific Co.). The
scintillation vial was shaken vigorously until the filter paper disintegrated, at which
time the radioactivity incorporated into the cells was counted in a Packard liquid
scintillation spectrometer.
The P-388 cell lines that grow as suspension cultures were maintained in T75 cul-
ture flasks. These cells were first labeled with (14C) ThdR for 24 hours, as in the case
ofmonolayer cultures. Following the removal of labeled medium by centrifugation,
the cells were washed, resuspended in fresh medium, and distributed into a number
of Falcon 25 cm2 tissue culture flasks to facilitate treating the cells with different
drug concentrations for a period of 30 minutes at37°C. After the drug treatment,
the cells were washed, resuspended in fresh medium in T25 flasks in a total volume
of 10 ml for each different drug concentration, and further incubated. From these
flasks, 3 ml cell samples (approximately 2 x 106/ml) were drawn at 0, 0.5, and 1.5
hours after treatment, pulsed with (3H) ThdR for 10 minutes, and processed for
scintillation counting as described above. The (3H) and (14C) counts for each sample
were obtained. The (3H)/(14C) ratio for each sample was calculated, expressed as a
percentage of the control, and plotted as a function of time.
RESULTS
The Correlation Between the Drug-Induced Inhibition ofDNA Synthesis
and Drug Sensitivity of Tumor Cells
The effects ofadriamycin on the rates ofDNA synthesis in ADR-sensitive(P-388/O)
and ADR-resistant (P-388/ADR) mouse leukemia cell lines were compared. In
P-388/O cells treated with three different concentrations ofADR, a dose- and time-
dependent inhibition of DNA synthesis was observed (Fig. IA). No inhibition of
DNA synthesis was observed in P-388/ADR cells treated with0.1 or 1.0Ag/ml ADR
(Fig. IB). However, at a higher concentration (5 /g/ml) of ADR, the inhibition of
DNA synthesis in P-388/ADR was almost as great as in P-388/O cells.
Similarly, the effects ofAra-C on DNA synthesis were compared in Ara-C-sensitive
(P-388/O) andAra-C-resistant (P-388/Ara-C) cell lines (Fig. 2). In Ara-C-resistant
cells there was a dramatic increase in the incorporation of label following the re-
moval of the drug. However, in P-388/O cells, practically no incorporation of (3H)
ThdR was seen 1.5 hours after Ara-C treatment.
The effects of MeCCNU on the incorporation of(3H) ThdR into sensitive (BE)
and resistant (HT-29) cell lines ofhuman colon cancer are shown in Figs. 3A and 3B,
respectively. The pattern oflabeling kinetics observed in this set of experiments ap-
pears to be similar to that of ADR effects in P-388 cells shown in Figs. IA and lB.
The MeCCNU treatment caused a significant dose-dependent decrease in the incor-
poration of(3H) ThdR into BE cells, while it had only a slight effect on the HT-29
cells.
The contrast between the response of sensitive and resistant cell lines to a given
drug becomes even more obvious when the difference between the rates of incor-
poration of(3H) ThdR at zero and 1.5 hours after the drug treatment is taken into
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FIG. 1. Effect of ADR on the incorporation of (3H) ThdR in the ADR-sensitive P-388/0 and the
ADR-resistant P-388/ADR mouse leukemia cells. A ten-minute pulse of (3H) ThdR was given at 0, 0.5,
and 1.5 hours after the removal of the ADR from the medium. The cells were treated with ADR for 30
minutes at concentrations of0.1 sg/ml, 0; 1.0 ig/ml, 0; and 5.0yig/ml, A. A (left). ADR-sensitive
P-388/0 mouse leukemia cells. B (right). ADR-resistant P-388/ADR mouse leukemia cells.
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FIG. 3. Effects of MeCCNU on the incorporation of (3H) ThdR in MeCCNU-sensitive BE cells and
MeCCNU-resistant HT-29 cells. The cells were treated with MeCCNU at concentrations of I Ag/ml, 0;
10 jg/ml, 0; and 100 /Ag/ml, A. A (left). MeCCNU-sensitive BE cells. B (right). MeCCNU-
resistant HT-29 cells.
consideration. This difference, which indicates the degree ofinhibition ofDNA syn-
thesis in each treatment, is calculated as follows:
Olo inhibition = Vi V Vf X 100 [a]
where Vi is the incorporation of (3H) ThdR (expressed as percentage of control) at
zero hour after drug treatment and Vf is the same parameter taken 1.5 hours later.
Using this formula, we calculated the percentage of inhibition of DNA synthesis
for ADR-sensitive and resistant P-388 cells from the data presented in Figs. IA and
IB, respectively(Fig. 4A). Particularly at a low concentration ofADR theinhibition
in P-388/ADR cells was less than 10 percent, whereas it ranged from 37 percent to
75 percent in the ADR-sensitive cells. A similar treatment ofthe data from Figs. 3A
and 3B brings into sharper focus the differences in the response of BE and HT-29
cells to MeCCNU (Fig. 4B). Increasing the concentration of MeCCNU had no sig-
nificant effect on the percentage of inhibition of DNA synthesis in the resistant
HT-29 cells; it remained less than 10 percent. In the sensitive BE cells the percentage
of inhibition increased with dose, i.e., from 23 percent to 33 percent.
Since there was an increase in the rate ofincorporation of(3H) ThdR into P-388/
Ara-C cells following treatment with Ara-C, the percentage ofincrease in DNA syn-
thesis was calculated as follows:
07o increase = V Vi x 100 [b] Vi
where V, and Vf are defined as in formula [a].830 BROWN AND RAO
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FIG. 4. Relative rates of inhibition of DNA synthesis in drug-sensitive (S) and resistant (R) cells at 1.5
hours after the drug treatment. A (left). Effect of ADR on P-388/0 (S) and P-388/ADR (R) cells.
Drug concentrations used were 0.1 yg/ml (low), 1.0 ug/ml (medium), and 5 jig/ml (high). B (right).
Effect ofMeCCNU on DNA synthesis in BE (S) and HT-29 (R) human colon cancer cells. The concentra-
tions of MeCCNU were 1 ug/ml (low), 10 yg/ml (medium), and 50 jig/ml (high). The formula for esti-
mating the percentage of increase is given in the Results section.
Application of this formula to the data from Fig. 2 provides a means to detect a
dose-dependent increase in the rate of incorporation of (3H) ThdR into Ara-C-
resistant cells (Fig. 5). There was practically no incorporation in the Ara-C-sensitive
cells.
DISCUSSION
The method of estimating the effects of anticancer drugs on the rate ofDNA syn-
thesis presented in this study appears to be capable of distinguishing drug-sensitive
cell lines from those that are resistant. When the percentage inhibition formula [a]
was used, inhibition ofDNA synthesis in ADR-sensitive P-388/0 cells at 0.1 and 1.0
jg/ml of ADR was seen to be significantly greater than in the ADR-resistant cells
(Fig. 4A). It should be noted that for the P-388/ADR cell line, the 1.5 hour time
point regarding (3H) ThdR incorporation was not significantly different from that
of the sensitive cell line at all three ADR concentrations tested (Figs. IA and iB).
However, when the difference in (3H) ThdR incorporation is observed over time, it
becomes easy to distinguish the sensitive cell line from the resistant cell line (Fig. 4A).
The observed difference is related to the mechanism of resistance that the P-388/
ADR cell line maintains.
The possible factors that render P-388/ADR cells resistant to ADR include de-
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creases in (i) permeability to the drug, (ii) drug retention by cells, and (iii) binding
affinities of the target molecules [5]. Recent reports suggest that decreased drug
retention by the cell via an enhanced efflux process is the most likely factor respon-
sible for drug resistance in P-388/ADR cells [7,8].
The data shown in Figs. IA and lB are best explained by an enhanced efflux
mechanism of resistance. At time zero, assuming that ADR treatment stimulates the
efflux mechanism, P-388/ADR drug-treated cells should have a lower cellular con-
centration of (3H) ThdR available for incorporation into DNA when compared to
the cellular (3H) ThdR levels of P-388/ADR cells not receiving the drug treatment,
yielding the results shown in Fig. lB. It would appear that at ADR concentrations
greater than 1ptg/ml, the efflux system is overloaded as ADR greatly depressed the
incorporation of (3H) ThdR over time when the 5,g/ml concentration of ADR was
used (Fig. iB).
In contrast, HT-29 cells seem to be resistant to MeCCNU even in higher concen-
trations. An increased dose ofMeCCNU did not significantly increase the inhibition
of DNA synthesis. In MeCCNU-sensitive BE cells, the drug effects were dose-
dependent. But even at the highest doses tested, the inhibition of (3H) ThdR uptake
in BE cells was only 33 percent, compared to 9 percent in the HT-29 cells. In spite of
the narrow differences, the pattern of DNA synthesis inhibition in drug-sensitive
cells is quite distinct from that observed in a resistant cell line.
These results confirm the observations of Painter and Painter and Howard [2-4],
who used this method to distinguish DNA-damaging compounds by measuring their
effects on DNA synthesis. They also reported that agents such as hydroxyurea and
cycloheximide, which inhibit DNA synthesis without causing any damage, show a
reverse effect, i.e., increase in the uptake of (3H) ThdR as a function of time. In our
study, we observed that P-388/O cells, which are sensitive to Ara-C, did not recover
at all following Ara-C treatment (Fig. 2). It appears that this cell line is extremely
sensitive to this drug. Even in the resistant line (P-388/Ara-C), incorporation of
(3H) ThdR immediately after the treatment exhibited a sharp decrease with increas-
ing drug concentration (Fig. 2). However, the recovery was dramatic and dose-
dependent (Fig. 5). The greater the inhibition at zero hours after treatment, the
higher the recovery 1.5 hours later. Thus, it is possible that the recovery of DNA
synthesis following treatment with other metabolic inhibitors such as hydroxyurea,
5-fluorouracil, or methotrexate may distinguish resistant cell lines from non-recov-
ering or poorly recovering sensitive cell lines. This, however, remains to be tested.
The dramatic recovery of DNA synthesis in the P-388/Ara-C cells that eventually
exceeded the rate of (3H) ThdR incorporation of the untreated control is difficult to
explain because of the complex and opposing effects that Ara-C has on ThdR incor-
poration [12]. However, a recent report demonstrated that reinitiation of DNA syn-
thesis occurred in some of the DNA segments that replicated earlier in the S phase as
a result of a 60-minute exposure of GK cells (EB virus-transformed human periph-
eral lymphocyte cell line) to Ara-C [9]. This aberrant double DNA replication ap-
pears to be the consequence of interruption of DNA replication rather than some
special property of the Ara-C molecule. Possibly when the Ara-C block is removed,
the number of replicating units synthesizing DNA increased in a dose-dependent
manner in comparison to the untreated control (Fig. 2).
Since we are able to distinguish drug-sensitive cell lines from the resistant ones, as
demonstrated in our study, we believe that this method could be applied to screen
human tumors rapidly for their drug sensitivity so that therapeutic regimens may be
designed on an individual basis. The possibility of applying such in vitro methods to
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predict the response ofhuman tumors to anticancer drugs appears to be very encour-
aging [10,111.
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